President Donald Trump has claimed credit for recent U.S. data indicating a decrease in prescription drug prices. In July, prices dropped by 0.8% and show a 3.1% reduction compared to the previous year. This marks the sharpest drop since 1963. The White House attributes the decline to Trump’s ‘most favored nation’ drug deals and the TrumpRx website, suggesting significant relief for American families.
However, drug pricing experts offer a nuanced perspective, suggesting multiple factors influence this trend. A law from President Joe Biden’s time in office that enabled Medicare to negotiate with pharmaceutical firms may also play a crucial role.
Experts note that generic and biosimilar products entering the market have spurred competition, thereby reducing prices for brand-name drugs. The prescription drug price index, released by the Labor Department, measures payments to pharmacies rather than consumer costs.
Competition and Policy Influence Prescription Drug Prices
Both market competition and policy changes significantly impact prescription drug prices. Experts highlight that generic competition, particularly for blockbuster products, leads to lower prices. Dr. Benjamin Rome of Harvard Medical School notes the arrival of biosimilar drugs targeting autoimmune conditions as an example.
Competition similarly reduces costs for drugs like Stelara, a biologic medicine treating chronic conditions, says health policy expert Stacie Dusetzina from Vanderbilt University.
Biden-era policies like the 2022 Inflation Reduction Act further influence prices by allowing Medicare to negotiate top-selling drug costs. New prices for negotiated drugs took effect in January, potentially affecting overall price trends. The Trump administration continues these mandated negotiations, forecasting further consumer savings in the coming years.
A new policy reducing GLP-1 weight loss drug prices for eligible Medicare enrollees started in July, reflected in last month’s data.
Measuring the Impact of MFN Deals and TrumpRx
The White House links the decrease to ‘most favored nation’ deals, aimed at aligning U.S. pharma prices with other developed nations. Yet, experts argue the impact remains unclear, as contracts are unpublished and MFN policies are still developing.
Stacie Dusetzina expressed skepticism about MFN policies affecting current payers, suggesting the Inflation Reduction Act’s policies and Medicare negotiations have a more direct impact.
Despite lauded transparency, experts remain uncertain about TrumpRx’s efficacy. The website claims $700 million in patient savings without detailing calculations. Democratic Sen. Elizabeth Warren has queried this claim, citing a lack of patient data storage.
Consumers Face High Costs Despite Falling Drug Prices
Although the consumer price index indicates dropping drug costs, consumers may not see this reflected in their expenses. Labor Department figures capture costs paid to pharmacies, not direct consumer payments. Insurance typically covers much of these costs, influenced by coverage specifics.
Experts caution that despite declining drug prices, higher health spending and policy changes result in increased premiums and out-of-pocket expenses for many. Dr. Benjamin Rome highlighted how the CPI fails to capture the consumer’s direct experience as accurately as tangible goods like groceries or fuel.
Leave a Reply